Nature Communications (Aug 2022)
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
- Alessandra Vergori,
- Alessandro Cozzi Lepri,
- Stefania Cicalini,
- Giulia Matusali,
- Veronica Bordoni,
- Simone Lanini,
- Silvia Meschi,
- Roberta Iannazzo,
- Valentina Mazzotta,
- Francesca Colavita,
- Ilaria Mastrorosa,
- Eleonora Cimini,
- Davide Mariotti,
- Lydia De Pascale,
- Alessandra Marani,
- Paola Gallì,
- AnnaRosa Garbuglia,
- Concetta Castilletti,
- Vincenzo Puro,
- Chiara Agrati,
- Enrico Girardi,
- Francesco Vaia,
- Andrea Antinori,
- HIV-VAC study group
Affiliations
- Alessandra Vergori
- HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Alessandro Cozzi Lepri
- Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL
- Stefania Cicalini
- HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Giulia Matusali
- Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Veronica Bordoni
- Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Simone Lanini
- HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Silvia Meschi
- Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Roberta Iannazzo
- HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Valentina Mazzotta
- HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Francesca Colavita
- Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Ilaria Mastrorosa
- HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Eleonora Cimini
- Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Davide Mariotti
- Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Lydia De Pascale
- HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Alessandra Marani
- Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Paola Gallì
- Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- AnnaRosa Garbuglia
- Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Concetta Castilletti
- Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Vincenzo Puro
- Risk Management Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Chiara Agrati
- Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Enrico Girardi
- Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Francesco Vaia
- Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- Andrea Antinori
- HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
- HIV-VAC study group
- DOI
- https://doi.org/10.1038/s41467-022-32263-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 13
Abstract
HIV infection may affect the immune response to vaccination. Here the authors show that humoral response in persons living with HIV after the third dose of a SARS-CoV-2 vaccine is strong and higher than that achieved with the second dose, while cell-mediated immunity remains stable.
